Olink Holding AB (publ) (NASDAQ:OLK) Stock Rating Reaffirmed by Canaccord Genuity Group

Olink Holding AB (publ) (NASDAQ:OLK)‘s stock had its “hold” rating reaffirmed by equities researchers at Canaccord Genuity Group in a research report issued on Tuesday, Benzinga reports. They presently have a $26.00 target price on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 10.17% from the stock’s previous close.

Olink Holding AB (publ) Stock Performance

Shares of OLK opened at $23.60 on Tuesday. The firm has a fifty day moving average of $23.96 and a 200-day moving average of $22.95. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -94.40 and a beta of 0.49. Olink Holding AB has a 1 year low of $14.10 and a 1 year high of $26.01.

Hedge Funds Weigh In On Olink Holding AB (publ)

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OLK. UBS Group AG grew its position in Olink Holding AB (publ) by 55.9% in the 3rd quarter. UBS Group AG now owns 5,700 shares of the company’s stock valued at $69,000 after buying an additional 2,043 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Olink Holding AB (publ) by 30.5% in the 4th quarter. Assetmark Inc. now owns 2,874 shares of the company’s stock worth $72,000 after acquiring an additional 672 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Olink Holding AB (publ) in the third quarter valued at approximately $76,000. Barometer Capital Management Inc. bought a new stake in Olink Holding AB (publ) during the fourth quarter worth approximately $116,000. Finally, US Bancorp DE lifted its position in Olink Holding AB (publ) by 874.4% in the second quarter. US Bancorp DE now owns 9,666 shares of the company’s stock worth $181,000 after purchasing an additional 8,674 shares during the period. 30.19% of the stock is owned by institutional investors.

About Olink Holding AB (publ)

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.